Epibatidine isomers and analogues: Structure-activity relationships

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 21, 2006, Pages 5493-5497

  White, Richard ^a   Malpass, John R ^a   Handa, Sandeep ^a   Richard Baker, S ^b   Broad, Lisa M ^b   Folly, Liz ^b   Mogg, Adrian ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Epibatidine analogues; Epibatidine isomers; nAChR affinity; Nicotinic receptor subtypes; Structure activity relationships

Indexed keywords

ALPHA3BETA4 NICOTINIC RECEPTOR; ALPHA4BETA2 NICOTINIC RECEPTOR; EPIBATIDINE; HOMOEPIBATIDINE; ISOEPIBATIDINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; EMBRYO; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION;

BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE; HUMANS; ISOMERISM; NICOTINIC AGONISTS; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33748790160     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.08.049     Document Type: Article

References (27)

1. Spande T.F., Garraffo H.M., Edwards M.W., Yeh H.J.C., Pannell L., and Daly J.W. J. Am. Chem. Soc. 114 (1992) 3475
2. For a review, see:. Jensen A.A., Frolund B., Liljefors T., and Krogsgaard-Larsen P. J. Med. Chem. 7 (2005) 565
3. For a review of epibatidine structure-activity relationships, see:. Carroll F.I. Bioorg. Med. Chem. Lett. 14 (2004) 1889 and 5713
4. For leading references to epibatidine analogue synthesis see:. Carroll F.I., Lee J.R., Navarro H.A., Ma W., Brieaddy L.E., Abraham P., Damaj M.I., and Martin B.R. J. Med. Chem. 45 (2002) 4755
5. Bunnelle W.H., Dart M.J., and Schrimpf M.R. Curr. Top. Med. Chem. 4 (2004) 299
6. For leading references to pharmacophore models and binding geometry, see:. Cashin A.L., Petersson J., Lester H.A., and Dougherty D.A. J. Am. Chem. Soc. 127 (2005) 350
7. Glennon R.A., and Dukat M. Bioorg. Med. Chem. Lett. 14 (2004) 1841
8. Crystal structure determinations of proteins which bind acetylcholine:. Hansen S.B., Sulzenbacher G., Huxford T., Marchot P., Taylor P., and Bourne Y. EMBO J. 24 (2005) 3635
9. See key references to earlier work in Ref. 5 (tropanes), and Ref. 7 (2-azanorbornanes).
10. The 'bicyclic effect' for the 7-nitrogen in the 7-azanorbornyl system was first proposed by. Lehn J.M. Fortsch. Chem. Forsch. 15 (1970) 311
11. This effect was invoked to explain unusually high nitrogen inversion barriers in this case. Barriers to inversion at nitrogen can be almost as high in 7-azanorbornanes as in aziridines (where the angle strain is much greater). The suggestion that contributions from ground-state stabilization in 7-azanorbornanes might be important was made by:. Nelsen S.F., Ippoliti J.T., Frigo T.B., and Petillo P.A. J. Am. Chem. Soc. 111 (1989) 1776
12. Durrant M.L., and Malpass J.R. Tetrahedron 51 (1995) 7063 (footnote 4e)
13. See also discussion in:. Davies J.W., Durrant M.L., Walker M.P., and Malpass J.R. Tetrahedron 48 (1992) 4379
14. Additional delocalization of electron density from nitrogen into the bicyclic framework is supported by the unusual deshielding of the bridging nitrogen in these systems:. Belkacemi D., Davies J.W., Malpass J.R., Naylor A., and Smith C.R. Tetrahedron 48 (1992) 10161
15. Malpass J. R.; Alkhuraiji, W. unpublished work.
16. Malpass J.R., Hemmings D.A., Wallis A.L., Fletcher S., and Patel S. J. Chem. Soc., Perkin Trans. 1 (2001) 1044
17. Malpass J.R., Handa S., and White R. Org. Lett. 7 (2005) 2759
18. Cox C.D., Malpass J.R., Rosen A., and Gordon J. J. Chem. Soc., Perkin Trans. 1 (2001) 2372
19. For work with compound 6 see:. Hodgson D.M., Maxwell C.R., Wisedale R., Matthews I.R., Carpenter K.J., Dickenson A.H., and Wonnacott S. J. Chem. Soc., Perkin Trans. 1 (2001) 3150
20. Malpass J.R., and White R. J. Org. Chem. 69 (2004) 5328
21. Badio B., Garraffo H.M., Plummer C.V., Padgett W.L., and Daly J.W. Eur. J. Pharmacol. 321 (1997) 189
22. White, R.; Malpass, J. R. Abstracts of papers, 230th National Meeting of the American Chemical Society, Washington DC, 2005; American Chemical Society: Washington, DC, 2005; abstract ORGN-645.
23. i values.
24. Bai D.L., Xu R., Chu G.H., and Zhu X.Z. J. Org. Chem. 61 (1996) 4600
25. Fitch R.W., Pei X.-F., Kaneko Y., Gupta T., Shi D., Federova I., and Daly J.W. Bioorg. Med. Chem. 12 (2004) 179
26. Zhou J., and Fu G.C. J. Am. Chem. Soc. 126 (2004) 1340
27. Cheng Y., and Prusoff W.H. Biochem. Pharmacol. 22 (1973) 3099